CVR – Talk Bio

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

3 weeks ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment

Lundbeck Fires First Shot in Bidding War With Alkermes Over Sleep Biotech Avadel

3 weeks ago talkbio0Tagged Alkermes, Approved, Avadel, bidding war, CVR, LUMRYZ, Lundbeck, Primary Hypersomnia, sleep biotech, United States Food and Drug Administration

Lundbeck; Alkermes; Avadel; bidding war; sleep biotech; Lumryz; idiopathic hypersomnia; FDA approval; deal; CVR

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

4 weeks ago talkbio0Tagged Acquisition, bidding war, CVR, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, regulatory certainty

Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

7 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Federal Judge Dismisses $6.4 Billion Lawsuit Against Bristol Myers Squibb Over Celgene Acquisition

1 year ago talkbio0Tagged BMS, Burning Mouth Syndrome, Celgene Acquisition, CVR, Drug Industry, federal, Judge, Legal Dispute, Myers, squibb

Bristol Myers Squibb (BMS), Celgene Acquisition, $6.4 Billion Lawsuit, Contingent Value Rights (CVR), Federal Judge Ruling, Pharmaceutical Industry, Legal Dispute